Eran Sadot1, Alexandre Doussot1, Eileen M O'Reilly2, Maeve A Lowery2, Karyn A Goodman3, Richard Kinh Gian Do4, Laura H Tang5, Mithat Gönen6, Michael I D'Angelica1, Ronald P DeMatteo1, T Peter Kingham1, William R Jarnagin1, Peter J Allen7. 1. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 7. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. allenp@mskcc.org.
Abstract
BACKGROUND: Reports show that FOLFIRINOX therapy for pancreatic ductal adenocarcinoma (PDAC) results in objective response rates two to threefold higher than those of other regimens. This study aimed to assess response and resection rates for locally unresectable (stage 3) patients initially treated with induction FOLFIRINOX. METHODS: The institutional cancer database was queried for patients treated with induction FOLFIRINOX therapy between 2010 and 2013. Patients were included in the study if they were treated at the authors' institution for stage 3 PDAC (locally unresectable) that had been adjudicated at a weekly multidisciplinary tumor board. RESULTS: The study identified 101 patients. The median age was 64 years (range 37-81 years), and the median follow-up period was 12 months (range 3-37 months). The patients received a median of six cycles (range 1-20 cycles) of induction FOLFIRINOX. No grade 4 or 5 toxicity was recorded. At the initial restaging (median of 3 months after diagnosis), 23 patients (23 %) had developed distant metastases, 15 patients (15 %) had undergone resection, and 63 patients (63 %) had proceeded to chemoradiation. In the group of 63 patients who had proceeded to chemoradiation (median of 9 months after diagnosis), an additional 16 patients (16 %) had undergone resection, and 5 patients (5 %) had developed metastases. A partial radiographic response was observed in 29 % of all the patients, which was associated with ability to perform resection (p = 0.004). The median overall survival time was 11 months for the group that progressed with FOLFIRINOX and 26 months for the group that did not progress. CONCLUSION: Nearly one third of the patients who had been initially identified as having stage 3 pancreatic carcinoma and had been treated with FOLFIRINOX responded radiographically and underwent tumor resection.
BACKGROUND: Reports show that FOLFIRINOX therapy for pancreatic ductal adenocarcinoma (PDAC) results in objective response rates two to threefold higher than those of other regimens. This study aimed to assess response and resection rates for locally unresectable (stage 3) patients initially treated with induction FOLFIRINOX. METHODS: The institutional cancer database was queried for patients treated with induction FOLFIRINOX therapy between 2010 and 2013. Patients were included in the study if they were treated at the authors' institution for stage 3 PDAC (locally unresectable) that had been adjudicated at a weekly multidisciplinary tumor board. RESULTS: The study identified 101 patients. The median age was 64 years (range 37-81 years), and the median follow-up period was 12 months (range 3-37 months). The patients received a median of six cycles (range 1-20 cycles) of induction FOLFIRINOX. No grade 4 or 5 toxicity was recorded. At the initial restaging (median of 3 months after diagnosis), 23 patients (23 %) had developed distant metastases, 15 patients (15 %) had undergone resection, and 63 patients (63 %) had proceeded to chemoradiation. In the group of 63 patients who had proceeded to chemoradiation (median of 9 months after diagnosis), an additional 16 patients (16 %) had undergone resection, and 5 patients (5 %) had developed metastases. A partial radiographic response was observed in 29 % of all the patients, which was associated with ability to perform resection (p = 0.004). The median overall survival time was 11 months for the group that progressed with FOLFIRINOX and 26 months for the group that did not progress. CONCLUSION: Nearly one third of the patients who had been initially identified as having stage 3 pancreatic carcinoma and had been treated with FOLFIRINOX responded radiographically and underwent tumor resection.
Authors: Stephen R Grobmyer; Fredric M Pieracci; Peter J Allen; Murray F Brennan; David P Jaques Journal: J Am Coll Surg Date: 2007-03 Impact factor: 6.113
Authors: Eileen M OʼReilly; Anna Perelshteyn; William R Jarnagin; Mark Schattner; Hans Gerdes; Marinela Capanu; Laura H Tang; Joseph LaValle; Corinne Winston; Ronald P DeMatteo; Michael DʼAngelica; Robert C Kurtz; Ghassan K Abou-Alfa; David S Klimstra; Maeve A Lowery; Murray F Brennan; Daniel G Coit; Diane L Reidy; T Peter Kingham; Peter J Allen Journal: Ann Surg Date: 2014-07 Impact factor: 12.969
Authors: Paolo Massucco; Lorenzo Capussotti; Antonella Magnino; Elisa Sperti; Marco Gatti; Andrea Muratore; Enrico Sgotto; Pietro Gabriele; Massimo Aglietta Journal: Ann Surg Oncol Date: 2006-09-06 Impact factor: 5.344
Authors: E Bajetta; M Di Bartolomeo; S C Stani; S Artale; S B Ricci; F Bozzetti; V Mazzaferro; L Toffolatti; R Buzzoni Journal: Int J Radiat Oncol Biol Phys Date: 1999-09-01 Impact factor: 7.038
Authors: Michelle L DeOliveira; Jordan M Winter; Markus Schafer; Steven C Cunningham; John L Cameron; Charles J Yeo; Pierre-Alain Clavien Journal: Ann Surg Date: 2006-12 Impact factor: 12.969
Authors: Javier Aristu; Rosa Cañón; Fernando Pardo; Rafael Martínez-Monge; Salvador Martin-Algarra; José Manuel Ordoñez; Elena Villafranca; Marta Moreno; Mauricio Cambeiro; Ignacio Azinovic Journal: Am J Clin Oncol Date: 2003-02 Impact factor: 2.339
Authors: John B Ammori; Lisa M Colletti; Mark M Zalupski; Frederic E Eckhauser; Joel K Greenson; Justin Dimick; Theodore S Lawrence; Cornelius J McGinn Journal: J Gastrointest Surg Date: 2003 Sep-Oct Impact factor: 3.452
Authors: William Small; Jordan Berlin; Gary M Freedman; Theodore Lawrence; Mark S Talamonti; Mary F Mulcahy; A Bapsi Chakravarthy; Andre A Konski; Mark M Zalupski; Philip A Philip; Timothy J Kinsella; Nipun B Merchant; John P Hoffman; Al B Benson; Steven Nicol; Rong M Xu; John F Gill; Cornelius J McGinn Journal: J Clin Oncol Date: 2008-02-20 Impact factor: 44.544
Authors: L Marthey; A Sa-Cunha; J F Blanc; M Gauthier; A Cueff; E Francois; I Trouilloud; D Malka; J B Bachet; R Coriat; E Terrebonne; C De La Fouchardière; S Manfredi; D Solub; C Lécaille; A Thirot Bidault; F Carbonnel; J Taieb Journal: Ann Surg Oncol Date: 2014-07-19 Impact factor: 5.344
Authors: Mustafa Suker; Berend R Beumer; Eran Sadot; Lysiane Marthey; Jason E Faris; Eric A Mellon; Bassel F El-Rayes; Andrea Wang-Gillam; Jill Lacy; Peter J Hosein; Sing Yu Moorcraft; Thierry Conroy; Florian Hohla; Peter Allen; Julien Taieb; Theodore S Hong; Ravi Shridhar; Ian Chau; Casper H van Eijck; Bas Groot Koerkamp Journal: Lancet Oncol Date: 2016-05-06 Impact factor: 41.316
Authors: Erqi L Pollom; Guanying Wang; Jeremy P Harris; Albert C Koong; Eran Bendavid; Jay Bhattacharya; Daniel T Chang Journal: Int J Radiat Oncol Biol Phys Date: 2017-01-07 Impact factor: 7.038
Authors: Lee M Ocuin; Jennifer L Miller-Ocuin; Stephanie M Novak; David L Bartlett; J Wallis Marsh; Allan Tsung; Kenneth K Lee; Melissa E Hogg; Herbert J Zeh; Amer H Zureikat Journal: HPB (Oxford) Date: 2016-07-08 Impact factor: 3.647
Authors: Walid L Shaib; Andrew Ip; Kenneth Cardona; Olatunji B Alese; Shishir K Maithel; David Kooby; Jerome Landry; Bassel F El-Rayes Journal: Oncologist Date: 2016-02-01